{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:08:01Z","timestamp":1790622481781,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,9,13]],"date-time":"2017-09-13T00:00:00Z","timestamp":1505260800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Alligator Bioscience"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s00262-017-2059-y","type":"journal-article","created":{"date-parts":[[2017,9,13]],"date-time":"2017-09-13T11:06:23Z","timestamp":1505300783000},"page":"47-60","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression"],"prefix":"10.1007","volume":"67","author":[{"given":"Jonathan P. O.","family":"Hebb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriane R.","family":"Mosley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Vences-Catal\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narendiran","family":"Rajasekaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ros\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Ellmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean W.","family":"Felsher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,13]]},"reference":[{"key":"2059_CR1","unstructured":"Hebb J, Kohrt H (2015) Systemic antitumor effects of intratumoral administration of the novel immunotherapeutic combination anti-CTLA4, anti-CD137, and anti-OX40 in mouse models of lymphoma and solid tumor [abstract]. In: American Society of Hematology 57th Annual Meeting; 2015 Dec 5\u20138; Orlando, FLA. Washington (DC): ASH; 2015. Abstract nr 1552. Blood, vol 126, no 23"},{"key":"2059_CR2","doi-asserted-by":"crossref","unstructured":"Hebb J, Mosley A, Vences Catalan F, Ellmark P, Norlen P, Felsher D (2016) Intratumoral administration of the immunotherapeutic combination anti-ctla4, anti-cd137 and anti-ox40: comparison to systemic administration, peri-draining lymph node injection, and cellular vaccine in a mouse lymphoma model [abstract]. In: American Society of Hematology 58th Annual Meeting; 2016 Dec 3-6; San Diego, CA. Washington (DC): ASH; 2016. Abstract nr 4172. Blood, vol 128, no 22","DOI":"10.1182\/blood.V128.22.4172.4172"},{"issue":"6165","key":"2059_CR3","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1126\/science.342.6165.1432","volume":"342","author":"J Couzin-Frankel","year":"2013","unstructured":"Couzin-Frankel J (2013) Breakthrough of the year 2013. Cancer immunotherapy. Science 342(6165):1432\u20131433","journal-title":"Science"},{"issue":"17","key":"2059_CR4","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","volume":"33","author":"MA Postow","year":"2015","unstructured":"Postow MA, Callahan MK, Wolchok JD (2015) Immune checkpoint blockade in cancer therapy. J Clin Oncol 33(17):1974\u20131982","journal-title":"J Clin Oncol"},{"issue":"5","key":"2059_CR5","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1158\/1078-0432.CCR-12-2214","volume":"19","author":"I Melero","year":"2013","unstructured":"Melero I, Grimaldi AM, Perez-Gracia JL, Ascierto PA (2013) Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res 19(5):997\u20131008","journal-title":"Clin Cancer Res"},{"key":"2059_CR6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3389\/fonc.2015.00034","volume":"5","author":"SN Linch","year":"2015","unstructured":"Linch SN, McNamara MJ, Redmond WL (2015) OX40 agonists and combination immunotherapy: putting the pedal to the metal. Front Oncol 5:34","journal-title":"Front Oncol"},{"key":"2059_CR7","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Lambotte O (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54:139\u2013148","journal-title":"Eur J Cancer"},{"issue":"5","key":"2059_CR8","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2016.25","volume":"13","author":"DN Khalil","year":"2016","unstructured":"Khalil DN, Smith EL, Brentjens RJ, Wolchok JD (2016) The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol 13(5):273\u2013290","journal-title":"Nat Rev Clin Oncol"},{"key":"2059_CR9","doi-asserted-by":"crossref","first-page":"76","DOI":"10.14694\/EdBook_AM.2015.35.76","volume":"35","author":"MA Postow","year":"2015","unstructured":"Postow MA (2015) Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book 35:76\u201383","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"2059_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00262-016-1909-3","volume":"66","author":"P Ellmark","year":"2017","unstructured":"Ellmark P, Mangsbo SM, Furebring C, Norlen P, Totterman TH (2017) Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation. Cancer Immunol Immunother 66(1):1\u20137","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"2059_CR11","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1080\/21645515.2015.1049779","volume":"11","author":"RH Pierce","year":"2015","unstructured":"Pierce RH, Campbell JS, Pai SI, Brody JD, Kohrt HE (2015) In-situ tumor vaccination: bringing the fight to the tumor. Hum Vaccin Immunother 11(8):1901\u20131909","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"2059_CR12","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10555-006-8503-7","volume":"25","author":"S Shu","year":"2006","unstructured":"Shu S, Cochran AJ, Huang RR, Morton DL, Maecker HT (2006) Immune responses in the draining lymph nodes against cancer: implications for immunotherapy. Cancer Metastasis Rev 25(2):233\u2013242","journal-title":"Cancer Metastasis Rev"},{"issue":"9","key":"2059_CR13","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1002\/ijc.27755","volume":"132","author":"MF Fransen","year":"2013","unstructured":"Fransen MF, Arens R, Melief CJ (2013) Local targets for immune therapy to cancer: tumor draining lymph nodes and tumor microenvironment. Int J Cancer 132(9):1971\u20131976","journal-title":"Int J Cancer"},{"issue":"1","key":"2059_CR14","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/1078-0432.CCR-13-0945","volume":"20","author":"Q Ye","year":"2014","unstructured":"Ye Q, Song DG, Poussin M, Yamamoto T, Best A, Li C, Powell DJ Jr (2014) CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin Cancer Res 20(1):44\u201355","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2059_CR15","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0002-9610(97)00139-6","volume":"174","author":"JT Vetto","year":"1997","unstructured":"Vetto JT, Lum S, Morris A, Sicotte M, Davis J, Lemon M, Weinberg A (1997) Presence of the T-cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers. Am J Surg 174(3):258\u2013265","journal-title":"Am J Surg"},{"key":"2059_CR16","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejca.2015.09.026","volume":"54","author":"A Makkouk","year":"2016","unstructured":"Makkouk A, Chester C, Kohrt HE (2016) Rationale for anti-CD137 cancer immunotherapy. Eur J Cancer 54:112\u2013119","journal-title":"Eur J Cancer"},{"issue":"8","key":"2059_CR17","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.4049\/jimmunol.172.8.4821","volume":"172","author":"P Bansal-Pakala","year":"2004","unstructured":"Bansal-Pakala P, Halteman BS, Cheng MH, Croft M (2004) Costimulation of CD8 T cell responses by OX40. J Immunol 172(8):4821\u20134825","journal-title":"J Immunol"},{"issue":"8","key":"2059_CR18","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1158\/1078-0432.CCR-16-1272","volume":"23","author":"NH Segal","year":"2017","unstructured":"Segal NH, Logan TF, Hodi FS, McDermott D, Melero I, Hamid O, Levy R (2017) Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody. Clin Cancer Res 23(8):1929\u20131936","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2059_CR19","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/cam4.732","volume":"5","author":"S Yun","year":"2016","unstructured":"Yun S, Vincelette ND, Green MR, Wahner Hendrickson AE, Abraham I (2016) Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials. Cancer Med 5(7):1481\u20131491","journal-title":"Cancer Med"},{"issue":"6230","key":"2059_CR20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP (2015) The future of immune checkpoint therapy. Science 348(6230):56\u201361","journal-title":"Science"},{"issue":"1","key":"2059_CR21","first-page":"13","volume":"50","author":"I Tirapu","year":"2002","unstructured":"Tirapu I, Mazzolini G, Rodriguez-Calvillo M, Arina A, Palencia B, Gabari I, Melero I (2002) Effective tumor immunotherapy: start the engine, release the brakes, step on the gas pedal,\u2026and get ready to face autoimmunity. Arch Immunol Ther Exp (Warsz) 50(1):13\u201318","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"4","key":"2059_CR22","doi-asserted-by":"crossref","first-page":"e19499","DOI":"10.1371\/journal.pone.0019499","volume":"6","author":"MA Curran","year":"2011","unstructured":"Curran MA, Kim M, Montalvo W, Al-Shamkhani A, Allison JP (2011) Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One 6(4):e19499","journal-title":"PLoS One"},{"issue":"5256","key":"2059_CR23","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","volume":"271","author":"DR Leach","year":"1996","unstructured":"Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271(5256):1734\u20131736","journal-title":"Science"},{"issue":"19","key":"2059_CR24","first-page":"5514","volume":"60","author":"J Kjaergaard","year":"2000","unstructured":"Kjaergaard J, Tanaka J, Kim JA, Rothchild K, Weinberg A, Shu S (2000) Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res 60(19):5514\u20135521","journal-title":"Cancer Res"},{"issue":"5","key":"2059_CR25","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1158\/1078-0432.CCR-14-1339","volume":"21","author":"M Dai","year":"2015","unstructured":"Dai M, Yip YY, Hellstrom I, Hellstrom KE (2015) Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies. Clin Cancer Res 21(5):1127\u20131138","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2059_CR26","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/BF00293985","volume":"16","author":"JE Schurig","year":"1986","unstructured":"Schurig JE, Florczyk AP, Bradner WT (1986) The mouse as a model for predicting the myelosuppressive effects of anticancer drugs. Cancer Chemother Pharmacol 16(3):243\u2013246","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"2059_CR27","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2326-6066.CIR-13-0067","volume":"2","author":"LC Sandin","year":"2014","unstructured":"Sandin LC, Orlova A, Gustafsson E, Ellmark P, Tolmachev V, Totterman TH, Mangsbo SM (2014) Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer. Cancer Immunol Res 2(1):80\u201390","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"2059_CR28","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1172\/JCI64859","volume":"123","author":"A Marabelle","year":"2013","unstructured":"Marabelle A, Kohrt H, Sagiv-Barfi I, Ajami B, Axtell RC, Zhou G, Levy R (2013) Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Investig 123(6):2447\u20132463","journal-title":"J Clin Investig"},{"issue":"8","key":"2059_CR29","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1158\/1078-0432.CCR-10-2888","volume":"17","author":"MF Fransen","year":"2011","unstructured":"Fransen MF, Sluijter M, Morreau H, Arens R, Melief CJ (2011) Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Clin Cancer Res 17(8):2270\u20132280","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2059_CR30","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/PAS.0000000000000453","volume":"39","author":"M Johncilla","year":"2015","unstructured":"Johncilla M, Misdraji J, Pratt DS, Agoston AT, Lauwers GY, Srivastava A, Doyle LA (2015) Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11 cases. Am J Surg Pathol 39(8):1075\u20131084","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"2059_CR31","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/ni.3159","volume":"16","author":"R Carretero","year":"2015","unstructured":"Carretero R, Sektioglu IM, Garbi N, Salgado OC, Beckhove P, Hammerling GJ (2015) Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat Immunol 16(6):609\u2013617","journal-title":"Nat Immunol"},{"issue":"20","key":"2059_CR32","doi-asserted-by":"crossref","first-page":"5994","DOI":"10.1158\/0008-5472.CAN-16-0549","volume":"76","author":"ME Rodriguez-Ruiz","year":"2016","unstructured":"Rodriguez-Ruiz ME, Rodriguez I, Garasa S, Barbes B, Solorzano JL, Perez-Gracia JL, Melero I (2016) Abscopal effects of radiotherapy are enhanced by combined immunostimulatory mabs and are dependent on CD8 T cells and crosspriming. Cancer Res 76(20):5994\u20136005","journal-title":"Cancer Res"},{"issue":"6","key":"2059_CR33","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.4049\/jimmunol.1502659","volume":"197","author":"AE Moran","year":"2016","unstructured":"Moran AE, Polesso F, Weinberg AD (2016) Immunotherapy expands and maintains the function of high-affinity tumor-infiltrating CD8 T cells in situ. J Immunol 197(6):2509\u20132521","journal-title":"J Immunol"},{"issue":"1","key":"2059_CR34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/eji.201343718","volume":"44","author":"SE Church","year":"2014","unstructured":"Church SE, Jensen SM, Antony PA, Restifo NP, Fox BA (2014) Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells. Eur J Immunol 44(1):69\u201379","journal-title":"Eur J Immunol"},{"issue":"3","key":"2059_CR35","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1084\/jem.190.3.355","volume":"190","author":"A Elsas van","year":"1999","unstructured":"van Elsas A, Hurwitz AA, Allison JP (1999) Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte\/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190(3):355\u2013366","journal-title":"J Exp Med"},{"issue":"4","key":"2059_CR36","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.4049\/jimmunol.169.4.1792","volume":"169","author":"RE Miller","year":"2002","unstructured":"Miller RE, Jones J, Le T, Whitmore J, Boiani N, Gliniak B, Lynch DH (2002) 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner. J Immunol 169(4):1792\u20131800","journal-title":"J Immunol"},{"key":"2059_CR37","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1471-2172-12-21","volume":"12","author":"XB Wang","year":"2011","unstructured":"Wang XB, Fan ZZ, Anton D, Vollenhoven AV, Ni ZH, Chen XF, Lefvert AK (2011) CTLA4 is expressed on mature dendritic cells derived from human monocytes and influences their maturation and antigen presentation. BMC Immunol 12:21","journal-title":"BMC Immunol"},{"issue":"2","key":"2059_CR38","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.coi.2013.01.004","volume":"25","author":"AE Moran","year":"2013","unstructured":"Moran AE, Kovacsovics-Bankowski M, Weinberg AD (2013) The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Curr Opin Immunol 25(2):230\u2013237","journal-title":"Curr Opin Immunol"},{"issue":"12","key":"2059_CR39","doi-asserted-by":"crossref","first-page":"6946","DOI":"10.1128\/IAI.68.12.6946-6953.2000","volume":"68","author":"J Wakeham","year":"2000","unstructured":"Wakeham J, Wang J, Xing Z (2000) Genetically determined disparate innate and adaptive cell-mediated immune responses to pulmonary Mycobacterium bovis BCG infection in C57BL\/6 and BALB\/c mice. Infect Immun 68(12):6946\u20136953","journal-title":"Infect Immun"},{"issue":"4","key":"2059_CR40","doi-asserted-by":"crossref","first-page":"e0153053","DOI":"10.1371\/journal.pone.0153053","volume":"11","author":"KN Kodumudi","year":"2016","unstructured":"Kodumudi KN, Siegel J, Weber AM, Scott E, Sarnaik AA, Pilon-Thomas S (2016) Immune checkpoint blockade to improve tumor infiltrating lymphocytes for adoptive cell therapy. PLoS One 11(4):e0153053","journal-title":"PLoS One"},{"issue":"1","key":"2059_CR41","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/jso.2930430104","volume":"43","author":"R Lafreniere","year":"1990","unstructured":"Lafreniere R, Borkenhagen K, Bryant LD (1990) MC-38 adenocarcinoma tumor infiltrating lymphocytes: correlation of cytotoxicity with time of tumor harvest after tumor inoculation. J Surg Oncol 43(1):8\u201312","journal-title":"J Surg Oncol"},{"issue":"6","key":"2059_CR42","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/CJI.0000000000000078","volume":"38","author":"M Zhang","year":"2015","unstructured":"Zhang M, Graor H, Visioni A, Strohl M, Yan L, Caja K, Kim JA (2015) T cells derived from human melanoma draining lymph nodes mediate melanoma-specific antitumor responses in vitro and in vivo in human melanoma xenograft model. J Immunother 38(6):229\u2013238","journal-title":"J Immunother"},{"issue":"4","key":"2059_CR43","doi-asserted-by":"crossref","first-page":"e23440","DOI":"10.4161\/onci.23440","volume":"2","author":"H Shirwan","year":"2013","unstructured":"Shirwan H, Sharma RK, Srivastava AK, Yolcu ES (2013) Co-stimulatory tumor necrosis factor ligands as adjuvants for the development of subunit-based anticancer vaccines. Oncoimmunology 2(4):e23440","journal-title":"Oncoimmunology"},{"issue":"7","key":"2059_CR44","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.4049\/jimmunol.1200597","volume":"189","author":"TH Schreiber","year":"2012","unstructured":"Schreiber TH, Wolf D, Bodero M, Gonzalez L, Podack ER (2012) T cell costimulation by TNFR superfamily (TNFRSF)4 and TNFRSF25 in the context of vaccination. J Immunol 189(7):3311\u20133318","journal-title":"J Immunol"},{"issue":"2","key":"2059_CR45","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1158\/0008-5472.CAN-13-2752","volume":"74","author":"J Duraiswamy","year":"2014","unstructured":"Duraiswamy J, Freeman GJ, Coukos G (2014) Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors\u2013response. Cancer Res 74(2):633\u2013634 (discussion 635)","journal-title":"Cancer Res"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-017-2059-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-017-2059-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-017-2059-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T15:47:25Z","timestamp":1602949645000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-017-2059-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,13]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["2059"],"URL":"https:\/\/doi.org\/10.1007\/s00262-017-2059-y","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,13]]}}}